Abstract:Parkinson's disease (PD) is a common degenerative disease of the central nervous system among the elderly. Istradefylline, an FDA-approved adenosine A(2A) receptor antagonist (anti-PD drug), has good efficacy. However, it has been reported that the double bond of istradefylline is easily converted into cis-configuration when exposed to an indoor environment or direct light in a dilute solution. In order to find more stable adenosine A(2A) receptor antagonists with similar pharmacological efficacy to istradefylline, the compounds series I-1 (12 compounds) was designed by maintaining the xanthine skeleton of istradefylline unchanged and replacing the trans-double bond with thiazole or benzothiazole and other biologically active heterocyclic compounds. These compounds were synthesized via multi-step experiment and successfully confirmed through different characterization techniques for their ability to inhibit cAMP formation in A(2A)AR overexpressing cells. The thiazole derivative of istradefylline (Compound I-1-11, I-1-12) exhibited significant activity (IC50 = 16.74 +/- 4.11 mu M, 10.36 +/- 3.09 mu M), as compared to istradefylline (IC50 = 5.05 +/- 1.32 mu M). In addition, the molecular docking of benzothiazole derivatives I-1-11 and thiazole derivatives I-1-12 with higher inhibition rate were carried out and compared with istradefylline. The molecular docking results showed that I-1-11 and I-1-12 anchored in the same site as that of XAC (3REY) with predicted affinity binding energy -6.63 kcal/mol and - 6.75 kcal/mol, respectively. Validation through dynamics simulation also showed stable interactions, with fluctuations <3 angstrom and MM/GBSA energy <-20 kcal/mol. Hence, this study could provide a basis for the rational design of adenosine A(2A) receptor antagonists with better potency.

Functional Reversal of (-)-stepholidine Analogues by Replacement of Benzazepine Substructure Using the Ring-Expansion Strategy.

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Molecular insights into the D1R agonist and D2R/D3R antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations

Dopamine D1 Receptor Agonist and D2 Receptor Antagonist Effects of the Natural Product (-)-stepholidine: Molecular Modeling and Dynamics Simulations.

Design, Synthesis and Evaluation of Benzo[a]thieno[3,2-G]quinolizines As Novel L-Spd Derivatives Possessing Dopamine D1, D2 and Serotonin 5-HT1A Multiple Action Profiles.

Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands

Dopamine D1receptor and Serotonin 5-Ht1areceptor Agonist Effects of the Natural Product (–)-Stepholidine: Molecular Modelling and Dynamics Simulations

Synthesis of 6-Substituted 1-Phenylbenzazepines and Their Dopamine D1 Receptor Activities

Biososteric Replacement in the Design and Synthesis of Ligands for Nicotinic Acetylcholine Receptors

Design and Synthesis of Five‐membered Heterocyclic Derivatives of Istradefylline with Comparable Pharmacological Activity

Structural Manipulation on the Catecholic Fragment of Dopamine D1 Receptor Agonist 1-Phenyl-n-methyl-benzazepines

Design, Synthesis, and Pharmacological Evaluation of Novel Tetrahydroprotoberberine Derivatives: Selective Inhibitors of Dopamine D1 Receptor

Reversal of subtype-selectivity and function by the introduction of a para -benzamidyl substituent to N -cyclopropylmethyl nornepenthone

1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, a novel compound class with potent chemoreversal activity

Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands

Synthesis and Biological Evaluation of a Series of Multi-Target N-substituted Cyclic Imide Derivatives with Potential Antipsychotic Effect

Replacement of Amide with Bioisosteres Led to a New Series of Potent Adenosine A2A Receptor Antagonists.

Design, Synthesis and Preliminary Bioactivity Evaluation of Bitopic Benzopyranomorpholine Analogues As Selective Dopamine D3 Receptor Ligands As Anti-Drug Addiction Therapeutic Agents

Design, Synthesis, and Biological Evaluation of Structurally Constrained Hybrid Analogues Containing Ropinirole Moiety As a Novel Class of Potent and Selective Dopamine D3 Receptor Ligands

Design, Synthesis, and Biological Evaluation of Benzofuran Derivatives As ET Receptor Antagonists

Copper-Catalyzed Nucleophilic Cycloisomerization Cascade Constructing Azepinoindolizine.